|
1
|
Ranganath R, Shah MA and Shah AR:
Anaplastic thyroid cancer. Curr Opin Endocrinol Diabetes Obes.
22:387–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keutgen XM, Sadowski SM and Kebebew E:
Management of anaplastic thyroid cancer. Gland Surg. 4:44–51.
2015.PubMed/NCBI
|
|
3
|
Glaser SM, Mandish SF, Gill BS,
Balasubramani GK, Clump DA and Beriwal S: Anaplastic thyroid
cancer: Prognostic factors, patterns of care and overall survival.
Head Neck. 38 Suppl 1:E2083–E2090. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Neill JP, Power D, Condron C,
Bouchier-Hayes D and Walsh M: Anaplastic thyroid cancer,
tumorigenesis and therapy. Ir J Med Sci. 179:9–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nambu J, Kobayashi T, Hashimoto M, Tashiro
H, Sugino K, Shimamoto F, Kikuchi A and Ohdan H: h-prune affects
anaplastic thyroid cancer invasion and metastasis. Oncol Rep.
35:3445–3452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Walsh MC, Lee J and Choi Y: Tumor necrosis
factor receptor- associated factor 6 (TRAF6) regulation of
development, function and homeostasis of the immune system. Immunol
Rev. 266:72–92. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun H, Li X, Fan L, Wu G, Li M and Fang J:
TRAF6 is upregulated in colon cancer and promotes proliferation of
colon cancer cells. Int J Biochem Cell Biol. 53:195–201. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han F, Zhang L, Qiu W and Yi X: TRAF6
promotes the invasion and metastasis and predicts a poor prognosis
in gastric cancer. Pathol Res Pract. 212:31–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin G, Huang C, Su G, Hu H and Xu H:
Effect of TRAF6 downregulation on malignant biological behavior of
lung cancer cell lines. Zhongguo Fei Ai Za Zhi. 18:661–667.
2015.(In Chinese). PubMed/NCBI
|
|
10
|
Sun H, Li XB, Meng Y, Fan L, Li M and Fang
J: TRAF6 upregulates expression of HIF-1α and promotes tumor
angiogenesis. Cancer Res. 73:4950–4959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weijts BG, Bakker WJ, Cornelissen PW,
Liang KH, Schaftenaar FH, Westendorp B, de Wolf CA, Paciejewska M,
Scheele CL, Kent L, et al: E2F7 and E2F8 promote angiogenesis
through transcriptional activation of VEGFA in cooperation with
HIF1. EMBO J. 31:3871–3884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khromova NV, Kopnin PB, Stepanova EV,
Agapova LS and Kopnin BP: p53 hot-spot mutants increase tumor
vascularization via ROS-mediated activation of the HIF1/VEGF-A
pathway. Cancer Lett. 276:143–151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han Q, Yao F, Zhong C and Zhao H: TRAF6
promoted the metastasis of esophageal squamous cell carcinoma.
Tumour Biol. 35:715–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo Z, Zhang X, Zeng W, Su J, Yang K, Lu
L, Lim CB, Tang W, Wu L, Zhao S, et al: TRAF6 regulates melanoma
invasion and metastasis through ubiquitination of Basigin.
Oncotarget. 7:7179–7192. 2016.PubMed/NCBI
|
|
15
|
Dong X, Fu J, Yin X, Cao S, Li X, Lin L,
Huyiligeqi and Ni J: Emodin: A review of its pharmacology, toxicity
and pharmacokinetics. Phytother Res. 30:1207–1218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu JM, Zhou J, Shi J, Xie JS, Huang L, Yip
AY, Loo WT, Chow LW and Ng EL: Emodin affects ERCC1 expression in
breast cancer cells. J Transl Med. 10 Suppl 1:S72012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Yu H, Zhang J, Ge X, Gao J, Zhang
Y and Lou G: Anti-tumor effect of emodin on gynecological cancer
cells. Cell Oncol (Dordr). 38:353–363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masaldan S and Iyer VV: Exploration of
effects of emodin in selected cancer cell lines: Enhanced growth
inhibition by ascorbic acid and regulation of LRP1 and AR under
hypoxia-like conditions. J Appl Toxicol. 34:95–104. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurata K, Onoda N, Noda S, Kashiwagi S,
Asano Y, Kawajiri H, Takashima T, Tanaka S, Ohsawa M and Hirakawa
K: Nestin expression as an independent indicator of poor prognosis
for patients with anaplastic thyroid cancer. Oncol Lett.
10:850–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim MS, Park MJ, Kim SJ, Lee CH, Yoo H,
Shin SH, Song ES and Lee SH: Emodin suppresses hyaluronic
acid-induced MMP-9 secretion and invasion of glioma cells. Int J
Oncol. 27:839–846. 2005.PubMed/NCBI
|
|
21
|
Huang PH, Huang CY, Chen MC, Lee YT, Yue
CH, Wang HY and Lin H: Emodin and Aloe-Emodin suppress breast
cancer cell proliferation through ER α Inhibition. Evid Based
Complement Alternat Med. 2013:3761232013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ok S, Kim SM, Kim C, Nam D, Shim BS, Kim
SH and Ahn KS, Choi SH and Ahn KS: Emodin inhibits invasion and
migration of prostate and lung cancer cells by downregulating the
expression of chemokine receptor CXCR4. Immunopharmacol
Immunotoxicol. 34:768–778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rong Y, Wang D, Wu W, Jin D, Kuang T, Ni
X, Zhang L and Lou W: TRAF6 is over-expressed in pancreatic cancer
and promotes the tumorigenicity of pancreatic cancer cells. Med
Oncol. 31:2602014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang T, Wang H and Han L: Expression and
clinical significance of tumor necrosis factor receptor-associated
factor 6 in patients with colon cancer. Iran Red Crescent Med J.
18:e239312016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang XL, Dang YW, Li P, Rong MH, Hou XX,
Luo DZ and Chen G: Expression of tumor necrosis factor
receptor-associated factor 6 in lung cancer tissues. Asian Pac J
Cancer Prev. 15:10591–10596. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen H, Feng J, Zhang Y, Shen A, Chen Y,
Lin J, Lin W, Sferra TJ and Peng J: Pien Tze Huang inhibits
hypoxia-induced angiogenesis via HIF-1 alpha/VEGF-A pathway in
colorectal cancer. Evid Based Complement Alternat Med.
2015:4542792015.PubMed/NCBI
|
|
27
|
Urbaniak-Kujda D, Kapelko-Slowik K, Prajs
I, Dybko J, Wolowiec D, Biernat M, Slowik M and Kuliczkowski K:
Increased expression of metalloproteinase-2 and −9 (MMP-2, MMP-9),
tissue inhibitor of metalloproteinase-1 and −2 (TIMP-1, TIMP-2) and
EMMPRIN (CD147) in multiple myeloma. Hematology. 21:26–33. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Wang H, Ke H and Ni S: MiR-129
regulates MMP9 to control metastasis of non-small cell lung cancer.
Tumour Biol. 36:5785–5790. 2015. View Article : Google Scholar : PubMed/NCBI
|
